Eli Lilly and Co. has reported promising results from its Phase 3 clinical trial of orforglipron, an oral GLP-1 medication designed to aid in diabetes management and weight loss, showing significant reductions in blood sugar levels and weight in individuals with Type 2 diabetes. The trial demonstrated that orforglipron effectively reduced A1C levels, aligning with the performance of existing injectable GLP-1 drugs, and represents a significant innovation by offering a more accessible oral alternative. If approved, orforglipron would become the second oral GLP-1 medication in the U.S., potentially expanding treatment options and providing a convenient alternative to injections for diabetes patients.